Version history

{
  "session_id": "sess_SDA-2026-04-04-frontier-connectomics-84acb35a_20260412-095156",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: Connectomics Hypotheses in Alzheimer's Disease Cognitive Decline\n\n---\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Tier 1 (Highest Priority)\n\n**Hypothesis 2 (Highest Translation Potential): Hippocampal-Cortical Memory Circuit Disconnection**\n\nThis is the most translationally ready of the six domains for the following reasons:\n- Structural disconnection between hippocampus, entorhinal cortex, and posteromedial parietal cortex is directly measurable with both DTI and high-resolution structural MRI\n- The hippocampus is the primary site of earliest measurable atrophy (entorhinal cortex layer II, CA1) and provides the clearest sequence: measurable disconnection precedes measurable cognitive decline by 1-2 years in ADNI data\n- Patient population fit is excellent: amnestic MCI populations with hippocampal disconnection are the exact populations where lecanemab and donanemab have demonstrated clinical benefit (TRAILBLAZER-ALZ 2, CLARITY-AD), and connectivity metrics can serve as enrichment biomarkers\n- Existing clinical infrastructure: hippocampal volume on MRI (FDA-qualified) and connectivity metrics using clinical 3T scanners are already standardized\n\n**Hypothesis 5: Sleep-Wake Cycle Disruption and Thalamic Connectivity**\n\nThis has high translation potential for distinct reasons:\n- The sleep-wake cycle offers a modifiable risk factor that may precede detectable neurodegeneration by years\n- Suvorexant (orexin receptor antagonist) is FDA-approved for insomnia in AD patients; mechanistic data suggest it may enhance N3 slow-wave sleep-dependent glymphatic clearance\n- A Phase 2 trial (NCT04639047) testing suvorexant in MCI/AD with amyloid biomarker endpoints provides a near-term regulatory pathway\n- Thalamic connectivity disruption is measurable with resting-state fMRI and is particularly relevant because the thalamus functions as a relay hub—making it both a contributor to and detector of distributed connectivity failure\n\n### Tier 2 (Important but requiring more validation)\n\n**Hypothesis 4: Functional Hyperconnectivity as Compensatory Mechanism vs. Early Pathology Marker**\n\nThe distinction between compensatory hyperconnectivity and early dysconnectivity is mechanistically important but clinically premature. However, this domain has value as an enrichment strategy: subjects showing hyperconnectivity in DMN regions despite amyloid positivity may represent a subpopulation with greater synaptic reserve, potentially explaining heterogeneity in anti-amyloid antibody response.\n\n---\n\n## 2. Clinical Evidence, Safety, and Patient Population by Hypothesis\n\n### Hypothesis 2: Hippocampal-Cortical Disconnection\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Clinical Evidence** | Strong. ADNI longitudinal data (n>1,000, 10+ year follow-up) consistently shows that ERC-CA1 structural connectivity loss predicts MCI-to-AD conversion better than hippocampal volume alone. Functional disconnection measured by rs-fMRI correlates with Word List Recall performance (r≈0.45). Tau PET (Braak",
  "tokens_used": "766"
}